Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Madrigal Pharmaceuticals (MDGL) Share Price
Media coverage about Madrigal Pharmaceuticals (NASDAQ:MDGL) has trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Madrigal Pharmaceuticals earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.0600723585237 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Separately, ValuEngine raised Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, May 19th.
Shares of Madrigal Pharmaceuticals (NASDAQ MDGL) opened at 17.08 on Friday. The firm’s market capitalization is $213.41 million. The stock’s 50 day moving average price is $15.94 and its 200 day moving average price is $15.75. Madrigal Pharmaceuticals has a 12-month low of $9.30 and a 12-month high of $18.24.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Thursday, August 10th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by $0.09. Equities research analysts expect that Madrigal Pharmaceuticals will post ($2.57) earnings per share for the current year.
In related news, Director Richard S. Levy acquired 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were bought at an average cost of $16.12 per share, for a total transaction of $32,240.00. Following the purchase, the director now owns 7,200 shares in the company, valued at approximately $116,064. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard S. Levy acquired 3,550 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were bought at an average price of $16.12 per share, for a total transaction of $57,226.00. Following the completion of the purchase, the director now owns 3,640 shares in the company, valued at approximately $58,676.80. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 9,100 shares of company stock worth $145,840. 66.40% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Madrigal Pharmaceuticals (MDGL) Share Price” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-madrigal-pharmaceuticals-mdgl-share-price/1535412.html.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.